Business Context and Reporting Period
Company: GSK plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: October 24, 2024
Subject: Announcement of new preliminary clinical data for Arexvy (respiratory syncytial virus vaccine) targeting expanded adult populations.
Key Financial Metrics
This filing is a current report regarding clinical trial results and does not contain financial statements. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Data
The filing details positive preliminary data from two clinical trials aimed at expanding the approved use of Arexvy:
- Adults Aged 18-49 at Increased Risk (Phase IIIb, NCT06389487): A single dose elicited robust immune responses in 395 participants with underlying medical conditions. The response was non-inferior to that observed in adults aged 60 and above, meeting co-primary endpoints.
- Immunocompromised Adults (Phase IIb, NCT05921903): In adults with kidney or lung transplants, a two-dose regimen elicited immune responses similar to a single dose in healthy adults aged 50+. Responses were consistent for RSV-A and RSV-B subtypes.
- Safety Profile: Safety and reactogenicity data were consistent with previous Phase III programs. Common adverse events included pain, fatigue, myalgia, arthralgia, and headache, most of which were transient and mild.
Outlook, Management Commentary, and Risks
Management Commentary: Tony Wood, Chief Scientific Officer, stated the data supports expanding protection to more adults at risk and provides insights into the impact of a second dose for certain populations. GSK is committed to working with regulators to facilitate label updates.
Regulatory Outlook: Final data will be submitted to the FDA and other regulators to support potential label updates for adults aged 18-49 at increased risk and immunocompromised adults. The vaccine is currently approved for adults 60+ globally and adults 50-59 at increased risk in the US and Europe.
Risks and Contingencies: The filing includes a standard cautionary statement regarding forward-looking statements. Actual results may differ due to risks described in GSK's 2023 Form 20-F and Q2 2024 results. There is no guarantee that a protective immune response will be elicited in all vaccinees.
Investor Verification Checklist
- Verify the timeline for FDA and global regulatory submissions for the expanded indications (adults 18-49 and immunocompromised).
- Monitor upcoming medical conferences for the presentation of final trial results.
- Assess the potential market size impact, noting the estimate of over 21 million adults aged 18-49 in the US with risk factors.
- Review the safety data in the final peer-reviewed publications to confirm consistency with preliminary findings.